Previous 10 | Next 10 |
Specialty healthcare-company Catalent (NYSE: CTLT) was looking anything but special to investors on Tuesday. Its share price saw a queasy drop of nearly 25% on the day, following the release of dispiriting quarterly results. For its first quarter of fiscal 2023, Catalent booked ...
Catalent, Inc. (CTLT) Q1 2023 Earnings Conference Call November 01, 2022 08:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Tom Castellano - Senior Vice President & Ch...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325 . UBX1325 is the company’s treatment in d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Catalent (NYSE: CTLT ) stock is falling hard on Tuesday as investors react to dismal results in its earnings report for the fiscal first quarter of 2023. The bad news for investors in CT...
The following slide deck was published by Catalent, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Catalent, Inc. 2023 Q1 - Results - Earnings Call Presentation
Contract manufacturer Catalent ( NYSE: CTLT ) is trading ~25% lower premarket trading on Tuesday after the company posted lower-than-expected Q3 result and lowered its 2023 revenue outlook, due to worsening macroeconomic conditions, including unfavorable foreign e...
Catalent press release ( NYSE: CTLT ): Q3 Non-GAAP EPS of $0.71 beats by $0.15 . Revenue of $1.02B (-2.9% Y/Y) misses by $60M . Updated FY'23 financial guidance projects net revenue of $4,625 million to $4,875 million from prior outlook of $4.975B-$5.225B vs. $...
Q1'23 net revenue of $1.02 billion, consistent with the prior-year period as reported, but increased 4% in constant currency, compared to Q1'22. Organic, constant-currency net revenue decreased by 1%, compared to Q1'22. Q1'23 net earnings of zero. Q1'23 Adj...
Catalent ( NYSE: CTLT ) is scheduled to announce Q1 earnings results on Tuesday, November 1st, before market open. The consensus EPS Estimate is $0.56 (-21.1% Y/Y) and the consensus Revenue Estimate is $1.08B (+4.9% Y/Y). Over the last 2 years, CTLT has beaten EPS es...
Summary Equity markets continued their downward slide during the quarter, as investors grew increasingly anxious over aggressive interest rate increases and the growing likelihood of a recession. The Strategy underperformed its benchmark, as positive contributions in industrials a...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...